MAG Antibody Testing
Test in Focus
Mayo Clinic Laboratories now offers an in-house ELISA assay to test for the presence of antibodies against myelin-associated glycoprotein (MAG) antibodies. In this episode of the “Answers From the Lab” podcast, John Mills, Ph.D., discusses how the semi-quantitative, calibrated assay uses unique, human MAG antigen that improves on earlier assays for detection of MAG antibodies. These antibodies are important biomarkers of the rare, hard-to-treat distal acquired demyelinating symmetric neuropathy (DADS).
Although DADS can theoretically be diagnosed through clinical presentation and nerve conduction studies, those finding are less straightforward in practice, says Dr. Mills. “They are complex and heterogenous, and this partly explains why there tends to be a two- to three-year lag in these patients from the time they present with the neuropathy until they formally are diagnosed with DADs or MAG neuropathy.”
Listen to learn more about how incorporating MAG antibody testing into the diagnostic workup can help guide clinicians to the correct diagnosis earlier, equipping them with confidence about disease presence to guide treatment decisions.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Evaluating peripheral neuropathy and paraproteinemic neuropathy.
Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.
Joseph Maleszewksi, M.D., and Marie-Christine Aubry, M.D., explain how Mayo Clinic Laboratory can provide definitive diagnosis of primary ciliary dyskinesia (PCD). Mayo Clinic's expertise and technology have earned the laboratory's designation as the sole center of excellence for diagnosing this rare respiratory disorder.
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.